W
Williamson Z. Bradford
Researcher at University of California, San Francisco
Publications - 80
Citations - 12332
Williamson Z. Bradford is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Idiopathic pulmonary fibrosis & Pirfenidone. The author has an hindex of 32, co-authored 80 publications receiving 10827 citations. Previous affiliations of Williamson Z. Bradford include University of Washington Medical Center & University of California, Berkeley.
Papers
More filters
Journal ArticleDOI
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis
Talmadge E. King,Williamson Z. Bradford,Socorro Castro-Bernardini,Elizabeth A. Fagan,Ian Glaspole,Marilyn K. Glassberg,Eduard Gorina,Peter Hopkins,David Kardatzke,Lisa Lancaster,David J. Lederer,Steven D. Nathan,Carlos Alberto de Castro Pereira,Steven A. Sahn,Robert Sussman,Jeffrey J. Swigris,Paul W. Noble +16 more
TL;DR: Pirfenidone, as compared with placebo, reduced disease progression, as reflected by lung function, exercise tolerance, and progression-free survival, in patients with idiopathic pulmonary fibrosis.
Journal ArticleDOI
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
Paul W. Noble,Carlo Albera,Williamson Z. Bradford,Ulrich Costabel,Marilyn K. Glassberg,David Kardatzke,Talmadge E. King,Lisa Lancaster,Steven A. Sahn,Javier Szwarcberg,Dominique Valeyre,Roland M. du Bois +11 more
TL;DR: In this article, the CAPACITY program was designed to confirm the results of a phase 2 study that suggested that pirfenidone, a novel antifibrotic and anti-inflammatory drug, reduces deterioration in lung function in patients with idiopathic pulmonary fibrosis.
Journal ArticleDOI
Incidence and Prevalence of Idiopathic Pulmonary Fibrosis
TL;DR: The results suggest that idiopathic pulmonary fibrosis is probably more common in the United States than previously reported.
Journal ArticleDOI
Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis.
Tasha E. Fingerlin,Elissa Murphy,Weiming Zhang,Anna L. Peljto,Kevin K. Brown,Mark P. Steele,James E. Loyd,Gregory P. Cosgrove,David A. Lynch,Steve D. Groshong,Harold R. Collard,Paul J. Wolters,Williamson Z. Bradford,Karl Kossen,Scott D. Seiwert,Roland M. du Bois,Christine Kim Garcia,Megan S. Devine,Gunnar Gudmundsson,Helgi J Isaksson,Naftali Kaminski,Yingze Zhang,Kevin F. Gibson,Lisa Lancaster,Joy D. Cogan,Wendi R. Mason,Toby M. Maher,Philip L. Molyneaux,Athol U. Wells,Miriam F. Moffatt,Moisés Selman,Annie Pardo,Dong Soon Kim,James D. Crapo,Barry J. Make,Elizabeth A. Regan,Dinesha Walek,Jerry Daniel,Yoichiro Kamatani,Diana Zelenika,Keith P Smith,David McKean,Brent S. Pedersen,Janet Talbert,Ravin N. Kidd,Cheryl Markin,Kenneth B. Beckman,Mark Lathrop,Mark Lathrop,Marvin I. Schwarz,David A. Schwartz +50 more
TL;DR: The results suggest that genes involved in host defense, cell-cell adhesion and DNA repair contribute to risk of fibrotic IIPs.
Journal ArticleDOI
A Placebo-Controlled Trial of Interferon Gamma-1b in Patients with Idiopathic Pulmonary Fibrosis
Ganesh Raghu,Kevin K. Brown,Williamson Z. Bradford,Karen M. Starko,Paul W. Noble,David A. Schwartz,Talmadge E. King +6 more
TL;DR: In a well-defined population of patients with idiopathic pulmonary fibrosis, interferon gamma-1b did not affect progression-free survival, pulmonary function, or the quality of life.